Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Finch Therapeutics Group Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Matt Blischak

İcra Kurulu Başkanı

US$775.7k

Toplam tazminat

CEO maaş yüzdesi	32.5%
CEO görev süresi	1.4yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	1.4yrs
Yönetim Kurulu ortalama görev süresi	6.1yrs

Son yönetim güncellemeleri

Recent updates

Finch to cut workforce by about 37% after Takeda ends bowel disease collaboration

Sep 01

Finch to get back rights to IBD product candidates after Takeda ends collaboration

Aug 25

Finch Therapeutics GAAP EPS of -$0.48 misses by $0.07, revenue of $0.36M

Aug 11

Here's Why We're Watching Finch Therapeutics Group's (NASDAQ:FNCH) Cash Burn Situation

Mar 15

Here's Why We're Watching Finch Therapeutics Group's (NASDAQ:FNCH) Cash Burn Situation

Dec 15

We Think Finch Therapeutics Group (NASDAQ:FNCH) Needs To Drive Business Growth Carefully

Aug 28

Finch Therapeutics: Gut Instinct Says Buy

Jun 14

CEO Tazminat Analizi

Matt Blischak'un ücretlendirmesi Finch Therapeutics Group'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$14m
Mar 31 2024	n/a	n/a	-US$16m
Dec 31 2023	US$776k	US$252k	-US$75m

Tazminat ve Piyasa: Matt 'ın toplam tazminatı ($USD 775.65K ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 677.23K ).

Tazminat ve Kazançlar: Matt şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.

CEO

Matt Blischak (61 yo)

1.4yrs

Görev süresi

US$775,651

Tazminat

Mr. Matthew P. Blischak, also known as Matt, JD, serves as Chief Executive Officer of Finch Therapeutics Group, Inc. since May 16, 2023 and serves as its President & Secretary since May 2023. He has intell...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Matthew Blischak	President	1.4yrs	US$775.65k	Veri yok
Lance Thibault	Chief Financial Officer	1.4yrs	US$168.79k	Veri yok
James Sigler	Executive Vice President of CMC	6.8yrs	Veri yok	Veri yok

1.4yrs

Ortalama Görev Süresi

61yo

Ortalama Yaş

Deneyimli Yönetim: FNCH 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.4 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jeffery Smisek	Independent Director	7.7yrs	US$2.29k	2.63% $ 509.2k
Chris Shumway	Independent Director	4.1yrs	US$2.29k	26.24% $ 5.1m
Christian Lange	Independent Chair	7.1yrs	US$2.29k	0% $ 0
Domenic Ferrante	Independent Director	5.1yrs	US$2.29k	1.32% $ 255.6k

6.1yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: FNCH 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.1 yıldır).

Finch Therapeutics Group Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Finch Therapeutics Group, Inc. Announces Resignation of Joseph Vittiglio as Chief Business and Legal Officer and Secretary, Effective December 31, 2022

High number of new directors

Finch Therapeutics Group, Inc. Announces Executive Appointments

High number of new directors

Key Executive recently bought US$12m worth of stock

Recent updates

Finch Therapeutics Group, Inc.(OTCPK:FNCH) dropped from NASDAQ Composite Index

Finch Therapeutics Group Receives the Delisting Letter from the Office of the General Counsel of Nasdaq Notifying the Listing Panel Determines to Delist the Company from Nasdaq

Nasdaq Listing Qualifications Department Issues an Additional Staff Determination to Finch Therapeutics Group for Continued Non-Compliance with the Market Value of Publicly Held Shares Rule

Finch Therapeutics Receives Notice from Nasdaq Regarding Non-Compliance with the Requirements of Nasdaq Listing Rule 5605(c)(2)

The Nasdaq Stock Market LLC Notifies Finch Therapeutics Regarding Company’s Status as 'Public Shell'

Finch Therapeutics Group Receives Non-Compliance Notice from Nasdaq

New major risk - Share price stability

Finch Therapeutics Announces 1-for-30 Reverse Stock Split of Common Stock to Satisfy the Minimum Price Requirement for Continued Listing on the Nasdaq Global Select Market

First quarter 2023 earnings released: US$1.33 loss per share (vs US$0.52 loss in 1Q 2022)

Finch Therapeutics Group, Inc. Reports Unaudited Consolidated Impairment of Long-Lived Assets for the First Quarter Ended March 31, 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

Finch Therapeutics Group, Inc. Announces Decision to Discontinue Phase 3 Trial of CP101 and Focus on Realizing the Value of Its Intellectual Property Estate and Other Assets

Finch Therapeutics Group, Inc. Announces Resignation of Joseph Vittiglio as Chief Business and Legal Officer and Secretary, Effective December 31, 2022

Price target decreased to US$12.00

Finch Therapeutics Group, Inc. Plans to Reduce its Workforce by Approximately 37%

Finch to cut workforce by about 37% after Takeda ends bowel disease collaboration

Finch to get back rights to IBD product candidates after Takeda ends collaboration

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Finch Therapeutics GAAP EPS of -$0.48 misses by $0.07, revenue of $0.36M

High number of new directors

Finch Therapeutics Group, Inc.(NasdaqGS:FNCH) dropped from Russell 2500 Value Index

Finch Therapeutics Announces Workforce Restructuring to Focus Resources on Key Development Programs

Price target decreased to US$27.67

Here's Why We're Watching Finch Therapeutics Group's (NASDAQ:FNCH) Cash Burn Situation

Finch Therapeutics Group, Inc. Pauses Enrollment in PRISM4 Its Phase 3 Clinical Trial of CP101 in Recurrent C. Difficile Infection

Finch Therapeutics Group, Inc. Announces Executive Appointments

Finch Therapeutics Group, Inc. Announces U.S. Patent and Trademark Office Grants Two New Patents for FIN-211

High number of new directors

Here's Why We're Watching Finch Therapeutics Group's (NASDAQ:FNCH) Cash Burn Situation

Third quarter 2021 earnings released: US$0.21 loss per share

We Think Finch Therapeutics Group (NASDAQ:FNCH) Needs To Drive Business Growth Carefully

Finch Therapeutics: Gut Instinct Says Buy

Key Executive recently bought US$12m worth of stock

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş